Latest Research And Development News

Page 3 of 115
Volt Group has lowered its FY26 revenue and EBITDA guidance after weaker-than-expected EcoQuip sales, despite reporting stronger year-to-date operating cashflow and solid growth from 4D Delta. The company is committing $3.0 million to expand and refurbish its mobile solar-lighting fleet as it tries to convert customer trials into revenue.
Victor Sage
Victor Sage
2 Nov 2026
ResMed has delivered a stronger first quarter for fiscal 2027, with revenue up 6% to US$1.415 billion and net income rising 20% to US$418 million. The headline result was helped by a preliminary gain on the MatrixCare sale, while the core Sleep and Breathing Health business continued to expand.
Ada Torres
Ada Torres
2 Nov 2026
Nodestream has completed its $6.5 million placement, launched Missions and expanded its defence push across the US and Europe. But revenue remains under pressure, quarterly cash burn is substantial and auditors have warned of material uncertainty over the company’s ability to continue as a going concern.
Sophie Babbage
Sophie Babbage
2 Nov 2026
Delorean’s flagship Salisbury bioenergy plant is 90% complete and now licensed to operate, while a proposed A$20 million Westpac facility could unlock its next major project. The catch is a quarterly operating cash outflow of A$2.52 million, leaving 2.52 quarters of funding on the company’s own calculation.
Victor Sage
Victor Sage
30 Oct 2026
Axtec has moved several proptech partnerships towards commercial rollout, but its September quarter cash position leaves just 0.58 quarters of estimated funding. The company is pursuing strategic investment and expects an R&D rebate, neither of which has been secured in the filing.
Victor Sage
Victor Sage
30 Oct 2026
Osteopore reported record quarterly revenue of A$859,000 in Q3 CY26 as it added market access in Thailand and Saudi Arabia and completed its first customised Hainan implant. The regenerative implant maker remains cash-flow negative, with A$712,000 in cash and A$14 million still available under its convertible note facility.
Victor Sage
Victor Sage
30 Oct 2026
Adherium delivered a fifth consecutive quarterly record for remote patient monitoring revenue, but ended September with only A$120,000 in cash after a A$3.499 million operating outflow. Post-quarter loans and an AstraZeneca milestone payment have improved near-term liquidity, although further funding remains central to the company’s plans.
Victor Sage
Victor Sage
30 Oct 2026
InteliCare ended the September quarter with A$1.394 million in cash after an operating cash outflow of A$1.271 million, leaving just 1.10 quarters of estimated funding. The company is relying on customer receipts from expanding deployments, while continuing to assess funding options.
Sophie Babbage
Sophie Babbage
30 Oct 2026
Proteomics International has begun the national rollout of its Promarker D and Promarker Eso blood tests through Healius, while a A$2 million tax incentive receipt has lifted pro forma cash to A$3.8 million. Promarker Endo also cleared an independent Oxford validation hurdle, but its commercial launch remains conditional.
Ada Torres
Ada Torres
30 Oct 2026
BauMart ended the September quarter with negative cash and cash equivalents of $199,000, despite raising $244,000 and repaying $250,000 of borrowings. The company expects an $80,000 modular-pilot inflow in December and plans another capital raising after its November AGM.
Victor Sage
Victor Sage
30 Oct 2026
Radiopharm Theranostics is preparing to start a pivotal RAD101 brain-metastases imaging trial in early 2027 after a successful FDA meeting. The clinical progress comes with a sharper funding question: the company reported A$7.46 million in cash against A$10.69 million of quarterly operating outflows, before a subsequent A$8 million tax-incentive-backed advance.
Ada Torres
Ada Torres
30 Oct 2026
Gold Hydrogen says its Ramsay project has demonstrated helium flow across three wells, with concentrations averaging 15.2% and modelled potential of up to 37 Mscf per well per day. The technical progress comes with a sharper financial constraint: cash fell to A$3.96 million, equal to only 0.57 quarters of reported funding, while a capital raising remains in prospect.
Maxwell Dee
Maxwell Dee
30 Oct 2026

Browse the archive

Full archive